AUTHORS
Jihye Yoon, BA, Elisabeth Denby2, Wei Yang3, Run Zhang4, Emily B. Casey5, Riddhi Patel6, J. Michael White7, Jeffrey Magee, MD, PhD8
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Pediatric acute myeloid leukemia (AML) can originate from fetal hematopoietic progenitors, yet congenital leukemias are exceedingly rare. This raises the question of whether fetal progenitors resist transformation prior to birth, even if descendants of the mutant fetal cells might rise to AML after birth. Indeed, we have recently shown that, in mice, KMT2A::MLLT1 expression conveys a selective disadvantage, rather than a selective advantage, to fetal progenitors that ultimately protects against AML. This barrier must be overcome, via other germline or acquired mutations, for transformation to occur (PMID: 41032751).
It is unclear whether fetal AML resistance extends to other driver mutations. For example, CBFA2T3::GLIS2 fusion protein has previously been shown to transform fetal progenitors more efficiently than adult progenitors (PMID: 31662298), as have NUP98 fusion proteins (PMID: 41351880). The association between NUP98 rearrangements (NUP98r) and fetal cell of origin is particularly striking because the incidence of NUP98r AML peaks in mid-childhood, with fewer than 10% of NUP98r AML presenting in children <1 year old. If NUP98r arise during fetal hematopoiesis, and fetal progenitors are readily transformed, then why is transformation deferred until later childhood in most cases? One possibility is that fetal progenitors are intrinsically more susceptible to transformation, but contextual factors, such as differentiation programs and competition with normal progenitors that are only evident in vivo, ultimately limit fetal leukemogenic potential.
We developed models to induce NUP98 fusion protein expression in hematopoietic progenitors during fetal, neonatal, juvenile, and adult stages of life. Importantly, fusion-expressing cells compete with normal hematopoietic cells in vivo, recapitulating leukemia initiation as it would occur during normal ontogeny. Through a series of multiomic and functional assays, we showed that a NUP98 fusion protein NUP98::HOXA9 (NHA9) drove excessive erythroid differentiation in fetal but not juvenile (P28) or adult (8-week and 6-month-old) progenitors. The fusion protein limited fetal hematopoietic stem cell (HSC) self-renewal capacity, ultimately depleting the fusion protein-expressing population relative to normal progenitors and precluding AML initiation. Juvenile and adult progenitors retained HSC self-renewal capacity and readily gave rise to AML.
The in vivo observations contrasted with effects of NHA9 on cultured fetal and juvenile progenitors. In ex vivo culture, NHA9 drove massive expansion of E14 and E18.5 fetal progenitors with concomitant increase in colony forming units. Cultured E14 cells readily engrafted irradiated recipient mice and gave rise to AML. In contrast, NHA9 did not immortalize juvenile (P28) progenitors to the same extent, and fusion protein expression was ultimately lost after 21 days in culture. Cultured P28 cells did not give rise to AML. Thus, fetal progenitors have intrinsically high capacity to self-renew and transform upon expression of NUP98 fusion protein, yet in the context of normal in vivo development, they are prone to erythroid differentiation.
Multiomic profiling of fetal NHA9-expressing progenitors revealed hyperactivation of erythroid differentiation programs, including transcription factors such as SOX6. Sox6 deletion partially restored HSC and myeloid progenitor cell numbers after fetal NHA9 induction, but it did not fully rescue normal fetal hematopoiesis or enable AML initiation. Thus, multiple transcription factors contribute to NHA9-driven erythroid differentiation.
We used the same modeling strategy to interrogate NUP98::KDM5A (NK), a NUP98 fusion that typically causes AMKL earlier in life, and MNX1, a non-NUP98r, non-KMT2A-rearranged oncoprotein that is overexpressed in t(7;12) infant AML. NK drove fetal erythroid differentiation much like NHA9, though HSC and myeloid progenitor depletion was less severe. In contrast, MNX1 did not deplete fetal HSCs and instead caused a myeloid differentiation block before birth. Thus, fetal regulatory programs promote differentiation in the setting of some, but not all, leukemogenic mutations.
DISCLOSURES
Jihye Yoon, BA: No relevant conflicts of interest to declare.